- Home
- AFCG vs IRWD Comparison
AFCG vs IRWD Comparison
Compare AFCG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFCG
- IRWD
- Stock Information
- Founded
- AFCG 2020
- IRWD 1998
- Country
- AFCG United States
- IRWD United States
- Employees
- AFCG N/A
- IRWD N/A
- Industry
- AFCG Real Estate Investment Trusts
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- AFCG Real Estate
- IRWD Health Care
- Exchange
- AFCG Nasdaq
- IRWD Nasdaq
- Market Cap
- AFCG 113.7M
- IRWD 111.2M
- IPO Year
- AFCG 2021
- IRWD 2010
- Fundamental
- Price
- AFCG $4.55
- IRWD $1.40
- Analyst Decision
- AFCG Hold
- IRWD Buy
- Analyst Count
- AFCG 5
- IRWD 5
- Target Price
- AFCG $8.17
- IRWD $4.94
- AVG Volume (30 Days)
- AFCG 364.8K
- IRWD 1.2M
- Earning Date
- AFCG 11-12-2025
- IRWD 11-06-2025
- Dividend Yield
- AFCG 13.54%
- IRWD N/A
- EPS Growth
- AFCG N/A
- IRWD N/A
- EPS
- AFCG N/A
- IRWD N/A
- Revenue
- AFCG $8,721,514.00
- IRWD $308,519,000.00
- Revenue This Year
- AFCG N/A
- IRWD N/A
- Revenue Next Year
- AFCG $13.23
- IRWD N/A
- P/E Ratio
- AFCG N/A
- IRWD N/A
- Revenue Growth
- AFCG N/A
- IRWD N/A
- 52 Week Low
- AFCG $3.44
- IRWD $0.53
- 52 Week High
- AFCG $10.88
- IRWD $5.13
- Technical
- Relative Strength Index (RSI)
- AFCG 49.95
- IRWD 66.63
- Support Level
- AFCG $4.37
- IRWD $1.05
- Resistance Level
- AFCG $4.70
- IRWD $1.35
- Average True Range (ATR)
- AFCG 0.24
- IRWD 0.09
- MACD
- AFCG -0.01
- IRWD 0.00
- Stochastic Oscillator
- AFCG 20.83
- IRWD 97.44
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.